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Abstract
Background: Desmoid tumors that present as a part of Gardener's syndrome can present very
difficult management problems.
Case presetation: We report a case of intra-abdominal desmoid tumor causing distal small bowel
obstruction that complicated the management of a more proximal enterocutaneous fistula from
the jejunum. After failure of more conventional management options including imatinib, the
patient's disease responded to doxorubicin and ifosfamide. The response resolved the bowel
obstruction and allowed small intestinal resection to resolve the enterocutaneous fistula.
Conclusion: Systemic cytotoxic therapy with doxorubicin and ifosfamide can be useful for patients
with complications from intra-abdominal desmoid tumor.
Background
Gardner's syndrome includes familial adenomatous poly-
posis with extracolonic manifestations, such as osteomas,
supernumerary teeth, fibrous dysplasia of the skull, fibro-
mas, and epidermoid cysts. Desmoid tumors, also known
as "aggressive fibromatosis", can have a significant impact
on the morbidity and mortality of patients with Gardner's
syndrome. Locally aggressive desmoid tumors can
impinge on surrounding structures, causing symptoms
and organ impairment. When treatment is indicated,
these tumors should be surgically resected with wide mar-
gins. However, resection is often followed by recurrence,
and resection of some lesions would cause unacceptable
deficits. Although desmoid tumors have no metastatic
potential, systemic therapy with a variety of agents can be
helpful. Cytotoxic chemotherapy is effective in some cases
refractory to more conservative treatment options. We
report a case of a 40 year-old woman with Gardner's Syn-
drome and desmoid tumors causing an enterocutaneous
fistula with distal small bowel obstruction, successfully
managed with a strategy that included cytotoxic chemo-
therapy.
Case presentation
A 40-year-old-woman with a history of Gardner's Syn-
drome status post prophylactic colectomy presented with
an enterocutaneous fistula and for reevaluation of
desmoid tumors. She had three previous abdominal oper-
ations including a prophylactic colectomy in 1992. In
1995, she had a resection of small intestine and marginal
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resection of associated desmoid tumors causing small
bowel obstruction. In 2002, an emergent resection of
small intestine and desmoid tumors for intestinal perfora-
tion removed only a portion of the diffuse mesenteric dis-
ease. This operation was complicated by an
enterocutaneous fistula from the jejunum that subse-
quently healed with conservative care. She had no adju-
vant radiation therapy at any point. Estrogen and
progesterone receptor expression of the tumors was never
assessed.
Despite treatment with anti-inflammatory agents, the
patient's abdominal desmoid tumors continued to grow
and she was re-admitted 10 months later for recurrence of
her enterocutaneous fistula. Radiographic studies showed
near-complete small bowel obstruction by desmoid
tumor (Figure 1, 2) and complete diversion of the fecal
stream through the fistula. She began total parenteral
nutrition (TPN). The fistula was not amenable to opera-
tive repair without resolution of the distal small bowel
obstruction. Options for resolving the distal obstruction
included operative resection of the desmoids, a procedure
associated with much potential morbidity, or systemic
therapy to reduce the size of the desmoids. The patient
was offered therapy with anti-estrogen agents or investiga-
tional therapy with imatinib. Imatinib was initiated and
was ineffective, possibly related to the patient's difficulty
with gut absorption. Imatinib was discontinued, and she
began a regimen of cytotoxic therapy that is active for sar-
coma, including doxorubicin 20 mg/m2 IV on days 1, 2,
and 3 and ifosfamide 2 g/m2 daily for 3 days of a 21 day
cycle. She received five cycles of this regimen, with a clear
radiographic response on CT scan (Figures 2, 3). However,
her high-output fistula continued.
A barium enema (Figure 4) demonstrated resolution of
the distal obstruction with reflux of contrast through the
fistula. Enterocutaneous fistula resection with primary
enteroenterostomy was performed without complication.
The patient was discharged on TPN for continued nutri-
tional support, although she was able to tolerate oral feed-
ings with normal bowel function. Her midline surgical
wound subsequently healed by secondary intent. With the
return of gastrointestinal function, antiestrogen therapy
with tamoxifen 20 mg po daily was initiated.
Discussion
Approximately 10% of patients with FAP develop
desmoid tumors as part of their extra-colonic manifesta-
tions [1]. Although they are histologically benign and typ-
ically slow-growing, desmoid tumors do have the capacity
to become locally aggressive. Treatment for desmoid
tumor is indicated for symptoms, risk to adjacent struc-
tures, or cosmesis. In this case, treatment of desmoid
tumor was indicated for small bowel obstruction caused
by desmoid tumor growth.
Surgical resection with negative pathologic margins is
optimal for treatment of most symptomatic desmoid
tumors [2]. Post-operative adjuvant radiation therapy
may be useful when macroscopic residual tissue is
present, particularly in areas with relatively radiation-tol-
erant surrounding normal tissues. For patients with large
tumors or impediments to complete resection, neoadju-
vant management with non-cytotoxic or cytotoxic agents
may be of benefit. Intra-abdominal desmoids in particular
are often not amenable to margin negative resection, and
in some instances cytotoxic chemotherapy has achieved
favorable results [3,4] In this case, chemotherapy reduced
the size of a tumor causing distal obstruction, allowing
bowel resection to resolve an enterocutaneous fistula.
For lesions requiring systemic therapy, hormonal therapy
including tamoxifen, toremifine, raloxifene, and progesti-
nal agents have been effective in a subset of patients [5-7].
Non-steroidal anti-inflammatory drugs may be used
alone or in combination with tamoxifen [8]. Sulindac is a
commonly used NSAID to treat desmoid tumors. Imat-
inib (Gleevec), a tyrosine kinase inhibitor, has been effec-
tive in treatment for desmoid and a phase II multicenter
trial investigating the activity of this agent is underway
[9,10].
Cytotoxic chemotherapy is indicated when other meas-
ures fail. There can be a significant increase in treatment-
related morbidity, which may be justified in some clinical
settings. Typically, initial treatment is low-dose systemic
chemotherapy to limit side-effects. For instance, treat-
ment with methotrexate and vinblastine given every 7–10
days for several months has stabilized advanced and
aggressive disease in some patients [11]. However,
responses are often slow and generally occur over many
months.
More intensive cytotoxic chemotherapy, such as the com-
bination of doxorubicin and dacarbazine, has been effec-
tive in patients who have unresectable disease that is
refractory to endocrine therapy, steroids and NSAIDs
[12,13]. Combination chemotherapy using doxorubicin
and ifosfamide produced a relatively rapid radiologic and
clinical response in our patient.
Although desmoid tumors have no metastatic potential,
they may often be locally aggressive, increasing the mor-
bidity and mortality of patients with Gardner's syndrome.
As we gain experience in detecting and treating adenoma-
tous disease early, we can expect the extra-colonic mani-
festations of Gardner's syndrome to play a greater role in
the prognosis of these patients. For desmoid tumors, treat-World Journal of Surgical Oncology 2006, 4:96 http://www.wjso.com/content/4/1/96
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Fistula injection with small bowel follow-through demon- strating distal obstruction of small bowel Figure 1
Fistula injection with small bowel follow-through demon-
strating distal obstruction of small bowel.
Computed tomogram of the abdomen prior to initiation of  cytotoxic chemotherapy demonstrating right-sided abdomi- nal wall soft tissue mass (16 × 9 cm) (arrow), and mesenteric  soft tissue mass (7 × 5 cm) Figure 2
Computed tomogram of the abdomen prior to initiation of 
cytotoxic chemotherapy demonstrating right-sided abdomi-
nal wall soft tissue mass (16 × 9 cm) (arrow), and mesenteric 
soft tissue mass (7 × 5 cm).
Computed tomogram of the abdomen at the same level as  Figure 2 following cytotoxic chemotherapy Figure 3
Computed tomogram of the abdomen at the same level as 
Figure 2 following cytotoxic chemotherapy. The largest 
abdominal wall lesion decreased to 13 × 7 cm (arrow). Other 
lesions in the rectus sheath decreased from 6.4 × 3.4 cm and 
4.4 × 2.7 cm to 6 × 3 cm and 3.3 × 2.2 cm, respectively. The 
mesenteric masses decreased markedly.
Follow-up barium enema revealing no evidence of distal  obstruction and anatomy suitable for segmental intestinal  resection of the enterocutaneous fistula Figure 4
Follow-up barium enema revealing no evidence of distal 
obstruction and anatomy suitable for segmental intestinal 
resection of the enterocutaneous fistula. Contrast refluxed 
from the anus through the previously obstructed area, and 
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ment options extend beyond surgical resection, radiation
therapy, and non-cytotoxic systemic therapies and can
include cytotoxic chemotherapy to the benefit of our
patients.
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